Back to Treatments

Treatment

Idecabtagene vicleucel (ide-cel)

1
Conditions
28
Trials
1,000
Participants
20%
Average Safety

Condition Evidence

Multiple myeloma

28 trials · 1,000 participants

95% effectiveness · 20% safety
Idecabtagene vicleucel (ide-cel) | DFDA